United Therapeutics Corporation (NASDAQ:UTHR) Receives $619.42 Consensus PT from Analysts

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have earned an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $646.00.

A number of research analysts have recently weighed in on UTHR shares. Cantor Fitzgerald lifted their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Royal Bank Of Canada lifted their target price on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, HC Wainwright upped their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $577.18, for a total value of $5,771,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,894,849.68. This represents a 34.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 613,218 shares of company stock worth $345,345,601 over the last quarter. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC grew its stake in United Therapeutics by 10.3% in the second quarter. GAMMA Investing LLC now owns 1,769 shares of the biotechnology company’s stock valued at $958,000 after purchasing an additional 165 shares in the last quarter. Versant Capital Management Inc raised its stake in shares of United Therapeutics by 93.6% during the 2nd quarter. Versant Capital Management Inc now owns 182 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 88 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in shares of United Therapeutics by 0.7% during the 1st quarter. Pacer Advisors Inc. now owns 243,545 shares of the biotechnology company’s stock valued at $144,417,000 after buying an additional 1,673 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of United Therapeutics by 2.8% during the 1st quarter. Parallel Advisors LLC now owns 1,056 shares of the biotechnology company’s stock valued at $626,000 after buying an additional 29 shares during the last quarter. Finally, NewEdge Advisors LLC grew its stake in shares of United Therapeutics by 24.7% in the 1st quarter. NewEdge Advisors LLC now owns 2,163 shares of the biotechnology company’s stock valued at $1,283,000 after buying an additional 428 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $563.70 on Friday. The firm has a 50 day simple moving average of $557.76 and a 200 day simple moving average of $528.73. United Therapeutics has a 52 week low of $272.12 and a 52 week high of $609.35. The company has a market cap of $23.93 billion, a PE ratio of 20.81, a price-to-earnings-growth ratio of 1.80 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.63 earnings per share. On average, equities analysts predict that United Therapeutics will post 26.63 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.